Get the Stockscreener App
1.41
7.24%
-0.11
Biomea Fusion Inc stock is traded at $1.41, with a volume of 1.20M.
It is down -7.24% in the last 24 hours and up +2.92% over the past month.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
See More
Previous Close:
$1.52
Open:
$1.53
24h Volume:
1.20M
Relative Volume:
0.61
Market Cap:
$99.69M
Revenue:
-
Net Income/Loss:
$-144.01M
P/E Ratio:
-0.3516
EPS:
-4.01
Net Cash Flow:
$-113.02M
1W Performance:
+15.57%
1M Performance:
+2.92%
6M Performance:
-45.98%
1Y Performance:
-75.69%
1-Day Range:
$1.41
$1.54
1-Week Range:
$1.19
$1.56
52-Week Range:
$0.8719
$6.06
Biomea Fusion Inc Stock (BMEA) Company Profile
Name
Biomea Fusion Inc
Sector
Industry
Phone
(650) 980-9099
Address
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.41 | 107.47M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-25 | Initiated | Jefferies | Buy |
| Jun-03-25 | Resumed | Piper Sandler | Overweight |
| Oct-09-24 | Initiated | Edward Jones | Buy |
| Sep-27-24 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Sep-27-24 | Upgrade | Truist | Hold → Buy |
| Aug-29-24 | Initiated | CapitalOne | Overweight |
| Jun-11-24 | Downgrade | Truist | Buy → Hold |
| Jun-07-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-24 | Initiated | Truist | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jun-26-23 | Downgrade | Jefferies | Buy → Hold |
| May-12-23 | Initiated | Barclays | Overweight |
| Mar-29-23 | Reiterated | Oppenheimer | Outperform |
| Mar-28-23 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-23 | Initiated | Citigroup | Buy |
| Jun-02-22 | Resumed | H.C. Wainwright | Buy |
| Jan-12-22 | Initiated | H.C. Wainwright | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Jefferies | Buy |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Biomea Fusion Inc Stock (BMEA) Latest News
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Biomea Fusion Inc - GuruFocus
Interim CEO & Director of Biomea Fusion Michael J. Hitchcock Buys 667% More Shares - simplywall.st
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 - The Manila Times
Biomea Fusion Highlights the Future of Menin Inhibitors and Icovamenib in Interview with Dr. Ralph DeFronzo at WCIRDC 2025 - Quiver Quantitative
Biomea Fusion (Nasdaq: BMEA) features KOL talk on menin, icovamenib at WCIRDC 2025 - Stock Titan
Biomea Fusion : WCIRDC 2025 COVALENT 111 Week 52 final Oral Presentation - marketscreener.com
Is Biomea Fusion Inc a good long term investmentEarnings Revision Updates & High Profit Market Growth - earlytimes.in
Biomea Fusion presents COVALENT-111 study results at WCIRDC - MSN
Biomea Fusion reports durable effects of diabetes drug 9 months after dosing - Investing.com Nigeria
Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025 - ts2.tech
Biomea Fusion Showcases Durable Benefits Of Menin Inhibitor In Type-2 Diabetes - RTTNews
Biomea Fusion stock soars after durable diabetes treatment results By Investing.com - Investing.com Nigeria
Biomea Fusion stock soars after durable diabetes treatment results - Investing.com
Biomea Fusion reports durable effects of diabetes drug 9 months after dosing By Investing.com - Investing.com South Africa
Biomea Fusion Presents Promising Results for Icovamenib in Treating Type 2 Diabetes at WCIRDC 2025 - Quiver Quantitative
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Is Biomea Fusion Inc. stock a buy before product launchesEarnings Recap Report & Weekly Top Gainers Alerts - Newser
BMEA Insider Trading - Quiver Quantitative
Biomea Fusion Interim CEO Increases Stake with 100,000 Shares Purchase - TradingView
BMEA: Advancing Menin and oral GLP-1 therapies for diabetes, with phase II trials and strong financial runway - TradingView — Track All Markets
Biomea Fusion (BMEA) Stock Analysis Report | Financials & Insights - Benzinga
Biomea Fusion Director Rainer M Erdtmann Acquires 50,000 Shares - TradingView
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion to present long-term diabetes drug data at WCIRDC - Investing.com Canada
Biomea Fusion announces breakthrough data presentation at WCIRDC - Traders Union
Biomea Fusion to Present Long-Term Icovamenib Data at 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease - Quiver Quantitative
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biomea Fusion (Nasdaq: BMEA) to present icovamenib β-cell data in insulin-deficient T2D - Stock Titan
Biomea Fusion (Nasdaq: BMEA) Grants 7,500-Share Inducement Option to New Employee - Stock Titan
Aisling Capital Management LP Purchases 1,250,000 Shares of Biomea Fusion, Inc. $BMEA - MarketBeat
Published on: 2025-11-30 10:58:22 - BỘ NỘI VỤ
Biomea Fusion Inc Stock Analysis and ForecastMoving Average Crossovers & Capital Allocation Recommendations - earlytimes.in
Why analysts remain bullish on Biomea Fusion Inc. stock2025 Market Trends & Real-Time Buy Signal Notifications - moha.gov.vn
Form 8-KCurrent report - ADVFN
Can Biomea Fusion Inc. stock outperform in 2025 bull marketTrade Entry Summary & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Will Biomea Fusion Inc. stock return to pre crisis levelsJuly 2025 Catalysts & Long-Term Safe Return Strategies - BỘ NỘI VỤ
Biomea Fusion set to engage at major investor conferences - Traders Union
Biomea Fusion (BMEA) Price Target Decreased by 10.64% to 7.14 - MSN
Biomea Fusion to Participate at Upcoming Investor Conferences - Investing News Network
Is the Smart Money Moving Into 52 Weeks Entertainment Limited Institutional Buying TrendsTechnical Analysis Insights & Fast Growing Investment Ideas - earlytimes.in
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan - MSN
Is Biomea Fusion Inc. a candidate for recovery playBreakout Watch & Capital Efficient Trade Techniques - newser.com
Is Biomea Fusion Inc. stock a dividend growth opportunity2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
Why Biomea Fusion Inc. stock could be next big winnerEarnings Overview Report & Low Risk High Win Rate Picks - newser.com
Biomea Fusion Inc Stock (BMEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):